TerminatedPhase 4NCT02041299
Efficacy and Safety of Ferriprox® in Patients With Sickle Cell Disease or Other Anemias
Studying Dietary iron overload disease
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- ApoPharma
- Principal Investigator
- Janet Kwiatkowski, MDChildren's Hospital of Philadelphia
- Intervention
- Deferiprone(drug)
- Enrollment
- 230 enrolled
- Eligibility
- 2 years · All sexes
- Timeline
- 2014 – 2019
Study locations (30)
- Children's Hospital Oakland, Oakland, California, United States
- University of Illinois at Chicago, Chicago, Illinois, United States
- Children's Hospital, New Orleans, Louisiana, United States
- University of Michigan Comprehensive Cancer Center, Ann Arbor, Michigan, United States
- Children's Hospital of Michigan, Detroit, Michigan, United States
- The Children's Hospital of Philadephia, Philadelphia, Pennsylvania, United States
- Thomas Jefferson University, Philadelphia, Pennsylvania, United States
- Medical University of South Carolina, Charleston, South Carolina, United States
- Centro Infantil Boldrini, Campinas, Brazil
- Hospital de Clínicas de Porto Alegre-HCPA,, Rio Branco, Brazil
- Instituto Estadual de Hematologia Arthur Siqueira Cavalcanti - HEMORIO, Rio de Janeiro, Brazil
- Casa de Saúde Santa Marcelina, São Paulo, Brazil
- Universidade Federal de São Paulo, São Paulo, Brazil
- Hospital for Sick Kids, Toronto, Ontario, Canada
- Mansoura University Children's Hospital, Al Mansurah, Egypt
- +15 more locations on ClinicalTrials.gov
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT02041299 on ClinicalTrials.govOther trials for Dietary iron overload disease
Additional recruiting or active studies for the same condition.